AGL 40.00 Decreased By ▼ -0.16 (-0.4%)
AIRLINK 129.53 Decreased By ▼ -2.20 (-1.67%)
BOP 6.68 Decreased By ▼ -0.01 (-0.15%)
CNERGY 4.63 Increased By ▲ 0.16 (3.58%)
DCL 8.94 Increased By ▲ 0.12 (1.36%)
DFML 41.69 Increased By ▲ 1.08 (2.66%)
DGKC 83.77 Decreased By ▼ -0.31 (-0.37%)
FCCL 32.77 Increased By ▲ 0.43 (1.33%)
FFBL 75.47 Increased By ▲ 6.86 (10%)
FFL 11.47 Increased By ▲ 0.12 (1.06%)
HUBC 110.55 Decreased By ▼ -1.21 (-1.08%)
HUMNL 14.56 Increased By ▲ 0.25 (1.75%)
KEL 5.39 Increased By ▲ 0.17 (3.26%)
KOSM 8.40 Decreased By ▼ -0.58 (-6.46%)
MLCF 39.79 Increased By ▲ 0.36 (0.91%)
NBP 60.29 No Change ▼ 0.00 (0%)
OGDC 199.66 Increased By ▲ 4.72 (2.42%)
PAEL 26.65 Decreased By ▼ -0.04 (-0.15%)
PIBTL 7.66 Increased By ▲ 0.18 (2.41%)
PPL 157.92 Increased By ▲ 2.15 (1.38%)
PRL 26.73 Increased By ▲ 0.05 (0.19%)
PTC 18.46 Increased By ▲ 0.16 (0.87%)
SEARL 82.44 Decreased By ▼ -0.58 (-0.7%)
TELE 8.31 Increased By ▲ 0.08 (0.97%)
TOMCL 34.51 Decreased By ▼ -0.04 (-0.12%)
TPLP 9.06 Increased By ▲ 0.25 (2.84%)
TREET 17.47 Increased By ▲ 0.77 (4.61%)
TRG 61.32 Decreased By ▼ -1.13 (-1.81%)
UNITY 27.43 Decreased By ▼ -0.01 (-0.04%)
WTL 1.38 Increased By ▲ 0.10 (7.81%)
BR100 10,407 Increased By 220 (2.16%)
BR30 31,713 Increased By 377.1 (1.2%)
KSE100 97,328 Increased By 1781.9 (1.86%)
KSE30 30,192 Increased By 614.4 (2.08%)

Pfizer Inc said on Thursday it had signed a $5.29 billion deal with the US government to deliver 10 million courses of its experimental COVID-19 antiviral drug, as the country rushes to secure promising oral treatments for the disease.

The deal is roughly twice the size of the contract the US government has with Merck & Co Inc, although the price for the Pfizer pill is lower at roughly $530 per course compared with about $700 for Merck's.

Pfizer applied for emergency authorization of the drug, branded as Paxlovid, this week after reporting data showing that it was 89% effective at preventing hospitalization or death in at-risk people.

The drugmaker said it would begin deliveries of the treatment as soon as this year if it is authorized by the US Food and Drug Administration.

"This agreement would help ensure millions of doses of this drug would be available to the American people if it is authorized," said Xavier Becerra, secretary of the United States Department of Health and Human Services.

While vaccinations against COVID-19 are a priority, having pills that can keep people out of the hospital "could be a lifesaver", Becerra said.

Pfizer, BioNTech, Moderna making $1,000 profit every second: analysis

Pfizer has said it expects to manufacture 180,000 treatment courses by the end of next month and at least 50 million courses by the end of 2022.

Countries have scrambled to secure doses of the Pfizer and Merck oral drugs, based on promising data reported by both companies.

The US government has so far secured 3.1 million courses of Merck's COVID-19 pill for $2.2 billion, with the right to buy 2 million more courses in the future.

Shares of Pfizer rose marginally to $51.18 premarket.

Comments

Comments are closed.